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In this study, Chen and colleagues
demonstrate chemical reprogramming of
human astrocytes into functional neurons
with a cocktail of small molecules. This
chemical reprogramming is mediated
through epigenetic silencing of glial
genes and transcriptional activation of
neural transcription factors such as
NeuroD1 and Neurogenin 2.
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We have recently demonstrated that reactive glial
cells can be directly reprogrammed into functional
neurons by a single neural transcription factor,
NeuroD1. Here we report that a combination of small
molecules can also reprogram human astrocytes in
culture into fully functional neurons. We demonstrate
that sequential exposure of human astrocytes to
a cocktail of nine small molecules that inhibit glial
but activate neuronal signaling pathways can suc-
cessfully reprogram astrocytes into neurons in
8-10 days. This chemical reprogramming ismediated
through epigenetic regulation and involves transcrip-
tional activation of NEUROD1 and NEUROGENIN2.
The human astrocyte-converted neurons can survive
for >5 months in culture and form functional synaptic
networks with synchronous burst activities. The
chemically reprogrammed human neurons can also
survive for >1 month in the mouse brain in vivo and
integrate into local circuits. Our study opens a new
avenue using chemical compounds to reprogram
reactive glial cells into functional neurons.
INTRODUCTION
Regeneration of functional neurons after brain injury remains a
major challenge for brain repair. Current efforts largely focus
on cell replacement therapy using exogenous cells derived
from embryonic stem cells or induced pluripotent stem cells
(iPSCs) to generate neurons (Sahni and Kessler, 2010; Takahashi
et al., 2007; Takahashi and Yamanaka, 2006). Despite great po-
tential, such cell transplantation approaches face significant hur-
dles such as immunorejection, tumorigenesis, and differentiation
uncertainty (Lee et al., 2013; Lukovic et al., 2014). Recent
studies, including our own, have demonstrated that astroglial
cells can be directly converted into functional neurons both
in vitro (Guo et al., 2014; Heinrich et al., 2010) and in vivo (Grande
et al., 2013; Guo et al., 2014; Liu et al., 2015; Torper et al., 2013).
We further demonstrated in a mouse model of Alzheimer’s dis-Cellease that reactive astrocytes can be directly reprogrammed
into functional neurons (Guo et al., 2014). Astrocytes can also
be converted first into neuroblast cells and then differentiated
into neuronal cells (Niu et al., 2013, 2015; Su et al., 2014). Similar
to astrocytes, NG2 glial cells have recently been converted into
neurons as well (Heinrich et al., 2014; Torper et al., 2015). How-
ever, so far conversion of glial cells into neurons has been largely
achieved using viral-based expression of transcription factors. In
contrast, small molecules have been used to promote neural dif-
ferentiation (Chambers et al., 2012), facilitate cell reprogramming
(Ladewig et al., 2012; Li et al., 2014; Liu et al., 2013), or even
directly reprogram fibroblasts into iPSCs (Hou et al., 2013), neu-
roprogenitor cells (NPCs) (Cheng et al., 2014), or neurons (Hu
et al., 2015; Li et al., 2015). Compared to transcription-factor-
based reprogramming, small molecules offer ease of use and a
broader range of downstream applications.
Here, we report a defined combination of small molecules
capable of directly reprogramming human astrocytes into func-
tional neurons after sequential administration. We tested a
variety of small molecules targeting signaling pathways impor-
tant for neurogenesis and identified a group of nine small mole-
cules that can reprogram human astrocytes into neurons. These
small-molecule-reprogrammed human neurons can survive
for >5months in culture and display robust synaptic activities. In-
jecting the human astrocyte-converted neurons into the mouse
brain in vivo revealed that these human neurons can integrate
into the local brain circuits. Together, our studies demonstrate
the feasibility of chemical reprogramming of human astrocytes
into functional neurons.
RESULTS
Reprogramming Human Astrocytes into Neurons by
Small Molecules
We have recently demonstrated that ectopic expression of a sin-
gle neural transcription factor, NeuroD1, can directly reprogram
glial cells into functional neurons (Guo et al., 2014). To investi-
gate whether small molecules can replace transcription factors
to chemically reprogram glial cells into neurons, we searched
the literature broadly to identify potential candidate molecules
for further functional screening. We selected 20 small molecules
as our starting candidate pool based on two major selection
criteria: one is that they inhibit glial signaling pathways, and theStem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc. 735
other is that they activate neuronal signaling pathways. Some
molecules were included because they can modulate DNA or
histone structure to increase reprogramming efficiency. The
20 small molecules selected for our initial screening were as
follows: SB431542, RepSox, LDN193189, dorsomorphin, N-[N-
(3,5-difluorophenacetyl)-L-alanyl]- S-phenylglycine t-butyl ester
(DAPT), BMS-299897, CHIR99021, TWS119, Thiazovivin (Tzv),
Y27632, Smoothened agonist (SAG), purmorphamine (Purmo),
TTNPB, retinoic acid (RA), valproic acid (VPA), forskolin, BIX
01294, RG-108, ISX9, and Stattic.
We mainly used human cortical astrocytes (HA1800,
ScienCell) in primary cultures for chemical reprogramming. Hu-
man astrocytes were isolated, passaged, and maintained in cul-
ture medium with 10% FBS to reduce possible contamination of
progenitor cells, because FBS stimulates differentiation of pro-
genitors. For initial testing, we applied a group of small mole-
cules together to human astrocyte cultures, but massive cell
death was observed after 2 days of drug treatment. To reduce
cell death, we added fewer small molecules at different time
points with different concentrations. After testing hundreds
of different conditions (see the Excel file ‘‘Small-Molecule
Screening Table’’ that accompanies the Supplemental Informa-
tion), we found a cocktail of nine small molecules (LDN193189,
SB431542, TTNPB, Tzv, CHIR99021, VPA, DAPT, SAG, and
Purmo) capable of reprogramming human astrocytes into neu-
rons when added in a stepwise manner (Figure 1A). This set of
nine small molecules is hereafter referred to as master conver-
sion molecules (MCMs). Specifically, human astrocytes were
first treated with LDN193189 (0.25 mM), SB431542 (5 mM),
TTNPB (0.5 mM), and Tzv (0.5 mM) for 2 days. SB431542 is an in-
hibitor of TGFb/activin receptors, which are involved in inhibiting
neuronal fate and promoting glial fate (Rodrı´guez-Martı´nez and
Velasco, 2012). Similarly, LDN193189 is an inhibitor of BMP re-
ceptors, which are important for astroglial differentiation (Gross
et al., 1996). TTNPB is an agonist of RA receptors, which are
crucial in neural patterning (Maden, 2002). We used the combi-
nation of LDN193189, SB431542, and TTNPB to initiate the re-
programming process by inhibiting glial signaling pathways
and activating neuronal signaling pathways simultaneously.
Tzv, an inhibitor of Rho-associated kinase (ROCK), promotes
cell survival and improves reprogramming efficiency (Lin et al.,
2009; Watanabe et al., 2007). Tzv was included throughout the
8 days of the reprogramming period. After an initial 2 days of
cell priming with LDN193189, SB431542, and TTNPB, these
three small molecules were replaced with CHIR99021 (1.5 mM),
DAPT (5 mM), and VPA (0.5 mM). CHIR99021 is an inhibitor of
glycogen synthase kinase 3 (GSK3). Inhibition of GSK3 signaling
promotes neuroprogenitor (NPC) homeostasis and neural induc-
tion (Hur and Zhou, 2010; Li et al., 2012). DAPT, a g-secretase
inhibitor that indirectly inhibits the Notch signaling pathway,
promotes neural differentiation (Borghese et al., 2010). VPA is
a histone deacetylase inhibitor that enhances reprogramming
efficiency (Huangfu et al., 2008). VPA was only included in the
reprogramming medium for 2 days because longer exposure
increased cell death, whereas CHIR99021 and DAPT were pre-
sent from D3–D6. On D7–D8, we used SAG (0.1 mM) and Purmo
(0.1 mM), two agonists for activating the sonic hedgehog (Shh)
signaling pathway, to complete the reprogramming process.
Shh signaling is a key determinant of neural patterning. SAG736 Cell Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inand Purmo have been used to induce neuronal differentiation
(Qu et al., 2014). At D9, we removed SAG and Purmo in the me-
dium, and replaced them with neurotrophic factors (brain-
derived neurotrophic factor [BDNF], neurotrophin 3 [NT3], and
Insulin-like growth factor 1 [IGF-1]) to promote neuronal matura-
tion after astrocyte-neuron conversion. The successful reprog-
ramming strategy is illustrated in Figure 1A.
The human astrocytes in our cultures were immunopositive for
astrocyte markers GFAP (79.3% ± 4.9%) and Glt1 (astrocyte-
specific glutamate transporter, 82.5% ± 4.3%) with no neurons
detected (Figures 1B and 1C). We found little contamination of
neural stem cells in our human astrocyte cultures as shown by
immunostaining with Sox2, Musashi, and Nestin (Figures S1A
and S1B), likely due to the presence of 10% FBS in our culture
medium. This was further confirmed after culturing human astro-
cytes for 1 month in neural differentiation medium supplemented
with growth factors (BDNF, NT3, and NGF) (Figures S1C–S1H).
In control medium without small molecules (1% DMSO), few
neurons were detected (Figure 1D); however, after sequentially
exposing cultures to small molecules, we found a large number
of cells that were immunopositive for neuronal markers such
as Doublecortin (DCX), b3-tubulin (Tuj1), MAP2, and NeuN (Fig-
ures 1E and 1F). The human astrocyte-converted neurons sur-
vived 4–5 months in our cultures and developed robust axons
and dendrites (Figure 1G). To visualize the conversion process
from astrocytes to neurons, we infected human astrocytes with
1 ml retroviruses encoding EGFP so that a small number of
EGFP+ live astrocytes were observed during time-lapse imaging
(Figure S2). Compared to controls (Figure S2A), small-molecule
treatment clearly changed astrocytes from a flat, polygonal
morphology to that of a neuronal morphology, with long neurites
at D8–D10 (Figures S2B–S2D). We further used GFAP::GFP
retrovirus to label the astrocytes (91% ± 6.7% of GFAP::GFP-in-
fected cells were GFAP+) and confirmed the astrocyte-neuron
conversion after small-molecule treatment (Figure 1H, 68.7% ±
4.2% NeuN+, n = 5 batches; see also Figures S2E–S2G). Similar
results were obtained using LCN2::GFP retrovirus (88.5% ± 3%
of LCN2::GFP-labeled cells were GFAP+) to trace astrocyte-
neuron conversion (Figures S2H–S2J, 54.4% ± 5.3% NeuN+,
n = 3 batches). The conversion efficiency obtained through line-
age tracing experiments was similar to the overall conversion ef-
ficiency induced by small-molecule treatment (Figures 1I and 1J;
control, 3.3% ± 0.5% Tuj1+, n = 4 batches; MCM, 67.1% ± 0.8%
Tuj1+, n = 4 batches; p < 0.0001, Student’s t test).
To investigatewhether human astrocytes fromdifferent origins
can be chemically reprogrammed into neurons, we obtained
human midbrain and spinal cord astrocytes from ScienCell.
Interestingly, humanmidbrain astrocytes were efficiently reprog-
rammed into neurons (Figures 1K–1M, Figures S3A–S3F),
whereas human spinal cord astrocytes were not (data not
shown), suggesting that our protocol is more suitable for astro-
cytes with human brain origin. To confirm this, we purchased hu-
man brain astrocytes fromGIBCO and found that they could also
be reprogrammed into neurons (Figures S3G–S3I). To test
whether human astrocytes might de-differentiate into NPCs,
we monitored Sox2, Nestin, Pax6, and Ki67 signals during the
chemical reprogramming process from D0 to D10, and
compared to those of NPCs (Figure S4). While Sox2 showed
some increase during reprogramming, it never reached the levelc.
Figure 1. Sequential Exposure to a Defined Group of Small Molecules Converts Human Astroglial Cells into Neuronal Cells
(A) Schematic illustration of our strategy to convert cultured human astrocytes into neurons using a cocktail of small molecules. Note that different subsets of
small molecules were used at different reprogramming stages.
(B andC) Quantitative analysis of the human astrocyte cultures (HA1800, ScienCell). Themajority of cells in our human astrocyte cultures were immunopositive for
astrocytic marker GFAP (79.3% ± 4.9%), astrocytic glutamate transporter GLT-1 (82.5% ± 4.3%), and to a lesser degree S100b (39.3% ± 1.8%). No cells were
immunopositive for neuronal markers NeuN, MAP2, or Doublecortin (DCX). HuNu, human nuclei, marker for human cells. n = 3 batches.
(D) Control human astrocyte cultures without small-molecule treatment had very few cells immunopositive for neuronal markers DCX (green), b3-tubulin (Tuj1,
red), or MAP2 (cyan).
(E) Sequential exposure of human astrocytes to small molecules resulted in amassive number of neuronal cells, which were immunopositive for DCX (green), Tuj1
(red), and MAP2 (cyan). MCM stands for master conversion molecules, including the nine small molecules used together for reprogramming. Samples were
analyzed at 14 days after initial small-molecule treatment.
(F) At 30 days post initial small-molecule treatment, human astrocyte-converted neurons developed extensive dendrites (MAP2, green) andwere immunopositive
for mature neuronal marker NeuN (red).
(G) Small-molecule-converted human neurons survived for 4 months in culture and showed robust dendritic trees (MAP2, green) as well as extensive axons
(SMI312, red).
(H) Astroglial lineage tracing with GFAP::GFP retrovirus showing that GFP+ cells were immunopositive for neuronal marker NeuN (red) after small-molecule
treatment. n = 5 batches.
(I and J) Small-molecule treatment achieved high conversion efficiency after cells were exposed to 8 days of MCM (67.1% ± 0.8%, Tuj1+ neurons/total cells
labeled by DAPI, n = 4 batches).
(K) Chemical reprogramming of human midbrain astrocytes into neurons. At 1 month post initial small-molecule treatment of human midbrain astrocytes
(ScienCell), most cells were immunopositive for neuronal marker NeuN (red) and MAP2 (green).
(L) Control human midbrain astrocyte cultures without small-molecule treatment had very few cells immunopositive for NeuN (red) or MAP2 (green) at 1 month of
culture in neuronal differentiation medium.
(M) Quantitative analysis revealed a large number of NeuN-positive neurons converted from human midbrain astrocytes at 1 month post small-molecule
treatment (199.7 ± 9.2 per 403 field), whereas the control group only had a few NeuN+ cells (5.6 ± 1.4 per 403 field). n = 4 batches.
Scale bars represent 50 mm for (B) and 20 mm for other images. ***p < 0.001, Student’s t test. Data are represented as mean ± SEM.of NPCs (Figures S4A and S4G). Nestin and Pax6 did not show
much increase during small-molecule treatment (Figures S4B,
S4C, S4H, and S4I). Ki67-labeled proliferating cells decreased
significantly after small-molecule treatment (Figures S4D and
S4J), suggesting that there was no expansion of progenitor cells
during chemical reprogramming. In addition, when we labeled
human astrocytes with BrdU before chemical treatment, manyCellconverted neurons were BrdU+ (Figures S4E and S4K); however,
when we labeled our cell culture with BrdU at D10 after small-
molecule treatment, essentially all converted neurons were
negative for BrdU (Figures S4F and S4K), suggesting that glia-
to-neuron conversion occurred during the presence of small
molecules. Taken together, these data indicatte that we have
developed a successful strategy using a defined combinationStem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc. 737
Figure 2. Functional Analyses of Human
Astrocyte-Converted Neurons Induced by
Small-Molecule Treatment
(A) Long-term survival of small-molecule-induced
human neurons (5 months in culture) and massive
number of synaptic puncta (SV2, red) along the
dendrites (MAP2, green). Scale bar represents
20 mm.
(B–D) Representative traces showing Na+ and K+
currents recorded from 1-month-old (B) and
2-month-old (C) human neurons induced by small
molecules. (D) shows the blockade of Na+ currents
by TTX (2 mM).
(E) Quantitative analyses of peak Na+ and K+ cur-
rents in 2-week-old to 3-month-old neurons con-
verted from human astrocytes by small molecules.
(F) Representative trace of repetitive action poten-
tials recorded in small-molecule-induced human
neurons at 75 days post initial drug treatment.
(G and H) Representative traces showing sponta-
neous synaptic events in 2-month-old converted
human neurons. Holding potential = 70 mV.
(H) Expanded trace from (G).
(I) Inhibitory GABAergic events revealed in human
astrocyte-converted neurons when holding poten-
tial was held at 0mV (2-month-old). The eventswere
blocked by GABAA receptor antagonist bicuculline
(BIC, 10 mM).
(J and K) Representative traces showing sponta-
neous burst activities in 3-month-old small-mole-
cule-induced human neurons. HP = 70mV.
(K) Expanded view of a burst in (J).
(L) The burst activities were blocked by TTX (2 mM).
The majority of synaptic events at 70 mV were
blocked by glutamate receptor antagonist DNQX
(10 mM), suggesting that they were glutamatergic
events.
(M) Dual whole-cell recordings illustrating that
small-molecule-converted human neurons formed
robust synaptic networks and fired synchronously.
(N) The Ca2+ ratio imaging further illustrating that
the small-molecule-converted human neurons
were highly connected and showed synchronous
activities.
Data are represented as mean ± SEM.of small molecules to chemically reprogram human astrocytes
into neurons.
Small-Molecule-Converted Human Neurons Are Fully
Functional
We next investigated whether the chemically reprogrammed
neurons are functional. We found that the small-molecule-con-
verted neurons survived for a long time (> 5 months) and
showed robust synaptic puncta along dendrites (Figure 2A).
Similarly, neurons reprogrammed from the midbrain human as-
trocytes and the human astrocytes of GIBCO also survived
more than 2 months in culture with many synaptic puncta along
dendrites (Figures S3F and S3I). Patch-clamp recordings re-
vealed significant sodium and potassium currents in astro-
cyte-converted neurons, which gradually increased during
neuronal maturation (Figures 2B–2E; 2-month: INa = 1,889 ±
197 pA, n = 10; IK = 2,722 ± 263 pA, n = 10). These neurons
were capable of firing repetitive action potentials (Figure 2F).738 Cell Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier InMore importantly, small-molecule-converted neurons showed
robust spontaneous synaptic events, including both excitatory
postsynaptic currents (EPSCs; frequency = 0.66 ± 0.14 Hz;
amplitude = 24.8 ± 8.2 pA, n = 15) (Figures 2G and 2H) and
inhibitory postsynaptic currents (IPSCs; frequency = 0.48 ±
0.21 Hz; amplitude = 23.3 ± 6.3 pA, n = 2) (Figure 2I). It is
noteworthy that, 3 months after initial small-molecule treat-
ment, the human astrocyte-converted neurons showed large
periodic burst activities, which were abolished by TTX or
DNQX (Figures 2J–2L), suggesting that these neurons formed
functional networks and started to fire synchronously together.
In support of this notion, we performed dual whole-cell record-
ings and demonstrated that two adjacent neurons showed
synchronous burst activities (Figure 2M). Furthermore, we
employed Fura-2 Ca2+ ratio imaging and recorded synchro-
nized Ca2+ spikes in the chemically reprogrammed neurons
(Figure 2N), indicating that these neurons have been function-
ally networked together. Therefore, human astrocytes can bec.
Figure 3. Characterization of the Human Astrocyte-Converted Neurons Induced by Small Molecules
(A–C) Immunostaining with anterior-posterior neuronal markers revealed that the small-molecule-converted human neurons were positive for forebrain marker
FoxG1 (A) but negative for hindbrain and spinal cord marker HOXB4 (B) and HOXC9 (C).
(D–F) Immunostaining with cortical neuronmarkers revealed that small-molecule-induced human neurons were negative for superficial layer marker Cux1 (D) but
positive for deep layer marker Ctip2 (E) and Otx1 (F).
(G and H) The small-molecule-converted human neurons were also immunopositive for general cortical neuron marker Tbr1 (G) and hippocampal neuron marker
Prox1 (H).
(I) Quantitative analyses of small-molecule-induced human neurons (FoxG1, 97.1% ± 1.1%, n = 3 batches; Cux1, 3.1% ± 1.9%, n = 4 batches; Ctip2, 71.4% ±
3%, n = 4 batches; Otx1, 87.4% ± 3.2%, n = 3 batches; Tbr1, 86.4% ± 3.4%, n = 3 batches; Prox1, 73.4% ± 4.4%, n = 4 batches). Scale bars represent 20 mm.
(J) MCM-converted human neurons were immunopositive for VGluT1.
(K) A small portion of MCM-converted human neurons were GAD67+.
(L–N) MCM-converted neurons were immunonegative for cholinergic neuronal marker vesicular acetylcholine transporter (VAChT) (L), dopaminergic neuronal
marker tyrosine hydroxylase (TH) (M), or spinal motor neuron marker Isl1 (N).
(O) Quantitative analyses of small-molecule-converted human neurons (VGluT1, 88.3% ± 4%, n = 4 batches; GAD67, 8.2% ± 1.5%, n = 4 batches). Scale bars
represent 20 mm.
Data are represented as mean ± SEM.chemically reprogrammed into fully functional neurons with
defined small molecules.
Small Molecules Reprogram Human Astrocytes into
Forebrain Glutamatergic Neurons
To characterize the neuronal properties after small-molecule-
induced reprogramming, we examined neuronal markers ex-
pressed from anterior to posterior nervous system. We found
that the majority of human astrocyte-converted neurons were
immmunopositive for forebrain marker FoxG1 (97.1% ± 1.1%,
Figure 3A, n = 3 batches), but negative for hindbrain and spinal
cordmarkers HoxB4 and HoxC9 (Figures 3B–3C, n = 3 batches).CellWe next performed a series of immunostaining with a variety of
cortical neuron markers. We found that the human astrocyte-
converted neurons were largely immunonegative for cortical
superficial layer marker Cux1 (Figure 3D) but positive for deep
layer markers Ctip2 (Figure 3E, 71.4% ± 3%, n = 5 batches)
and Otx1 (Figure 3F). The human astrocyte-converted neurons
were also immunopositive for forebrain neuronal marker Tbr1
(Figure 3G, 86.4% ± 3.4%, n = 3 batches), as well as hippocam-
pal neuronal marker Prox1 (Figure 3H). Figure 3I shows the
quantitative results. Therefore, our chemically reprogrammed
neurons are mainly forebrain deep layer neurons or hippocampal
neurons.Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc. 739
We further investigated neuronal subtypes based on the neu-
rotransmitters they contain. We found that the majority of small-
molecule-reprogrammed neurons were immunopositive for
glutamatergic neuronmarker VGluT1 (Figure 3J). A small fraction
of the converted neurons were immunopositive for GABAergic
neuron marker GAD67 (Figure 3K). On the other hand, the astro-
cyte-converted neuronswere largely immunonegative for cholin-
ergic marker VAChT (Figure 3L), dopaminergic marker tyrosine
hydroxylase (TH) (Figure 3M), or spinal motor neuron marker
Isl1 (Figure 3N). The quantitative analyses of the neuronal sub-
types were shown in Figure 3O (VGlut1, 88.3% ± 4%, n = 4
batches; GAD67, 8.2% ± 1.5%, n = 4 batches). These results
suggest that the glutamatergic neurons are themajor subtype re-
sulting from use of our small-molecule reprogramming protocol.
Different small molecules may be required to reprogram human
astrocytes into other neuronal subtypes.
Activation of Endogenous Neural Transcription Factors
during Chemical Reprogramming
To understand the molecular mechanisms of chemical reprog-
ramming, we first employed PCR Array (QIAGEN) to investigate
gene profile changes. At D4 after small-molecule treatment, we
found a dramatic increase, up to 300-fold, in the transcriptional
levels of several neural transcription factors including NGN1/2,
NEUROD1, and ASCL1, as well as immature neuronal marker
DCX (Figure 4A). At D8, the most significant change at the tran-
scriptional level was the immature neuronal gene DCX, which
showed a 2,000-fold increase (Figure 4B), suggesting that the
majority of newly converted cells are immature neurons by the
end of small-molecule treatment. In contrast, the glia-related
genes were generally downregulated (Figures 4A and 4B). We
then performed quantitative real-time PCR experiments to
examine the time course of transcriptional changes of NGN2,
NEUROD1, and astroglial genes GFAP and ALDH1L1 during the
chemical reprogramming process (Figures 4C–4F). Interestingly,
we found that NGN2 transcription peaked at D4 (Figure 4C), while
NEUROD1 peaked at D6 during small-molecule treatment (Fig-
ure 4D), consistent with their sequential expression during early
brain development. As for glial genes, the GFAP transcriptional
level was significantly reduced over 200-fold at D4 (Figure 4E),
coinciding with the activation of neural transcription factors (Fig-
ures 4C and 4D). Similarly, the transcriptional level of another as-
trocytic gene, ALDH1L1, was also downregulated (Figure 4F). In
contrast, control experiments without small-molecule treatment
showed little transcriptional changes (Figures S5A–S5F). There-
fore, our small-molecule treatment activates neural transcrip-
tional factors and in the meantime inhibits astrocytic genes.
Epigenetic Regulation during Chemical Reprogramming
Wenext investigated whether epigenetic regulationwas involved
in our chemical reprogramming. DNA methylation in the gene
promoter affects the accessibility of transcription factor binding
and hence becomes a rate-limiting factor in reprogramming of
pluripotent stem cells (Papp and Plath, 2013; Yao and Jin,
2014). We performed methylated DNA immunoprecipitation fol-
lowed by sequencing (MeDIP-seq) to examine the methylation
level of genes of interest before and after small-molecule treat-
ment. As expected, the promoter region of the GFAP gene was
initially unmethylated in human astrocytes before small-mole-740 Cell Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Incule treatment (D0), but a clear increase of methylation was
detected at D8 of small-molecule treatment (Figure 4G). This
increased methylation was further confirmed by targeted bisul-
fite sequencing (BS-seq) (Figure 4H). Notably, this GFAP pro-
moter region contains the transcription factor binding sites for
STAT3 and AP1, which have been shown to play a critical role
in the activation of the GFAP gene (Cheng et al., 2011; Condorelli
et al., 1994). BS-seq data revealed that the flanking sites of the
STAT3 and AP1 binding region were hypermethylated (Fig-
ure 4H), which could explain why GFAP transcription was signif-
icantly downregulated after small-molecule treatment (Figure 4E)
(Xu et al., 2015). Our MeDIP-seq also revealed an increase of
DNA methylation at the GFAP transcription start site (TSS) after
small-molecule treatment, which was also confirmed by BS-
seq (Figure 4I). In contrast to glial gene GFAP, neuronal gene
neurofilament-M (NEFM), a midsized neurofilament gene spe-
cific to neurons, showed a decrease of methylation signal at
the promoter region after small-molecule treatment (Figures 4J
and 4K), suggesting the activation of neuronal genes. We also
investigated epigenetic regulation of transcription factor NGN2,
an important gene involved in neuronal differentiation. MeDIP-
seq analyses indicated that the methylation level of the NGN2
promoter region was quite low before and after small-molecule
treatment (data not shown), consistent with a previous report
(Hirabayashi et al., 2009). As an alternative to DNA methylation,
histone modification can also regulate gene expression. There-
fore, we further investigated histone modification of the NGN2
promoter region and TSS (Figures 4L–4O). Consistent with the
application of HDAC inhibitor VPA during our chemical reprog-
ramming process, we observed a significant increase of histone
acetylation at D8 (Figure 4M). Interestingly, the H3K4me3 level
significantly increased at the promoter region (Figure 4N),
whereas the H3K27me3 level significantly decreased at the
TSS at D8 (Figure 4O), consistent with transcriptional activation
of NGN2 induced by small-molecule treatment. Together, our re-
sults suggest that both transcriptional and epigenetic regulations
are involved in our chemical reprogramming process.
To corroborate with our transcriptional and epigenetic ana-
lyses, we further performed immunostaining to examine the
protein expression changes during the chemical reprogramming
process (Figure 5). We found that the Ascl1 expression level first
showed a significant increase after 2 day treatment with
LDN193189, SB431542, and TTNPB (Figures 5A and 5G). The
expression level of Ngn2 showed a peak at D4 after small-
molecule treatment (Figures 5B and 5H; in the presence of
CHIR99021, DAPT, and VPA). Compared to Ascl1 and Ngn2,
the expression of NeuroD1 appeared to be delayed, with a peak
level reached at D6 after small-molecule treatment (Figures 5C
and 5I), consistent with our transcriptional studies (Figures 4C
and 4D). In addition, immunostaining experiments also revealed
that some cells started to show neuronal markers such as DCX
at D4–D6 (Figure 5D), and NeuN+ neurons appeared at D8–D10
(Figures 5E and 5J), which is after the peak expression of
NeuroD1. In contrast to the increase of neuronal markers, astro-
cytic protein GFAP showed a significant decrease after small-
molecule treatment (Figures 5F and 5K), consistent with epige-
netic silencing and transcriptional downregulation of the GFAP
gene. Control astrocytes cultured for 10 dayswithout small-mole-
cule treatment did not showmuch change in the expression levelc.
Figure 4. Transcriptional and Epigenetic Regulation during Chemical Reprogramming of Human Astrocytes into Neurons
(A and B) PCR array revealed substantial transcriptional activation of neural transcription factors (NGN1/2, NEUROD1, and ASCL1) and immature neuronal gene
DCX at day 4 (A) or day 8 (B) after small-molecule treatment. Note that DCX increased >2,000-fold at D8 compared to the control. The genes showing significant
change in PCR array assay were presented (p < 0.05, Mann-Whitney t test).
(C–F) The time course of transcriptional changes revealed by quantitative real-time PCR analyses. Neural transcriptional factors NGN2 (C) and NEUROD1 (D)
showed a peak transcription at D4 and D6, respectively; whereas astroglial genes GFAP (E) and ALDH1L1 (F) were significantly downregulated. *p < 0.05,
**p < 0.01, ***p < 0.001; two-way ANOVA followed with Dunnett’s test. n = 3 batches.
(G–I) Epigenetic regulation of GFAP promoter and transcription start site (TSS) during chemical reprogramming. MeDIP-seq revealed a significant increase of
methylation in the GFAP promoter region (G, box region) after 8 days of small-molecule treatment, which was confirmed by subsequent BS-seq (H). Note that the
hypermethylated sites were located in the flanking region of two important transcription factor-binding sites, STAT3 and AP1, which will significantly inhibit the
transcription of GFAP. BS-seq also showed a significant increase of the methylation level at GFAP TSS and 50 UTR regulatory region (I), further suggesting an
inhibition of GFAP transcription through DNA methylation.
(J and K) MeDIP-seq and BS-seq revealed a significant decrease of methylation at the promoter region of a neuronal gene NEFM (neurofilament-M), suggesting
transcriptional activation of neuronal genes during chemical reprogramming of human astrocytes into neurons.
(L and M) CHIP-qPCR revealed a significant increase of histone acetylation in the NGN2 promoter region after small-molecule treatment, likely caused by HDAC
inhibitor VPA.
(N and O) The methylation level of H3K4 increased significantly in the NGN2 promoter region (N), whereas H3K27 methylation at the NGN2 TSS showed a
significant decrease (O), indicating epigenetic activation of NGN2 through histone modification.
Data are represented as mean ± SEM.of neural transcription factors, neuronal protein NeuN, or astro-
cytic protein GFAP (Figure S6). These experiments suggest that
our small-molecule strategy has successfully activated endoge-
nous neural transcription factors, which may play an important
role in the reprogramming of astrocytes into neurons.CellThe Functional Role of Each Individual Compound
during Chemical Reprogramming
To dissect out the precise contribution of each single molecule
toward reprogramming, we performed a series of experiments
by withdrawing each individual compound from our cocktailStem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc. 741
Figure 5. Increase of the Protein Expression Level of Neural Transcription Factors during Chemical Reprogramming
(A–C) Representative images illustrating the gradual activation of endogenous neural transcription factors Ascl1 (A), Ngn2 (B), and NeuroD1 (C) at different days of
small-molecule treatment.
(D and E) Representative images showing the gradual increase of neuronal signal DCX (D) and NeuN (E) during the conversion process from D0 to D10.
(F) Representative images showing the decrease of astrocytic marker GFAP from D0 to D10. Scale bars represent 20 mm.
(G–I) Quantitative analyses of the protein expression level of Ascl1 (G), Ngn2 (H), and NeuroD1 (I). Note that Ascl1 significantly increased at D2 by 3-fold, while
Ngn2 peaked at D4 and NeuroD1 peaked at D6. n = 3 batches.
(J) Quantified data showing a significant increase of NeuN from D6 to D10. n = 3 batches.
(K) Quantified data showing a significant decrease of GFAP from D0 to D10. n = 3 batches.
Data are represented as mean ± SEM.pool (Figure 6). Compared to the sequential exposure to nine
molecules in total, removing DAPT resulted in a most significant
reduction of the number of converted neurons (Figures 6A–6C).
Similarly, removing CHIR99021, SB431542, or LDN193189
also significantly reduced the reprogramming efficiency (Figures
6D–6F). Removing VPA or SAG+Purmo slightly reduced the re-
programming efficiency (Figures 6G and 6H). Interestingly,
removing Tzv or TTNPB did not have a significant effect on the
astrocyte-neuron reprogramming (Figures 6I and 6J). Figure 6K
illustrates the summarized data of drug-withdrawing experi-
ments. While it is not a surprise that Tzv had no effect, since it
mainly acts as a cell-survival factor, it is quite unexpected to
find that removing TTNPB had no effect. We included TTNPB
because it is an agonist of RA receptors, which were found to
play an important role in neural differentiation. The lack of contri-
bution of TTNPB suggested that RAmay not be a necessary fac-
tor in reprogramming astrocytes into neurons. On the other
hand, the inhibition of Notch signaling, GSK3b, and BMP/TGFb
signaling pathways appeared to be important for reprogramming
astrocytes into neurons. To ensure that these signaling pathways742 Cell Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inare indeed inhibited during our small-molecule treatment, we
performed a series of immunostains against phosphorylated
SMAD1/5/9, Notch intracellular domain (NICD), and phosphory-
lated GSK3b (Figures S5G–S5I). Our results showed that the
BMP/TGFb, Notch, and GSK3b signaling pathways were signif-
icantly inhibited (Figures S5G–S5I) after small-molecule treat-
ment, suggesting a close link between the inhibition of these
signaling pathways and the astrocyte-to-neuron conversion.
In Vivo Integration of HumanNeurons in theMouseBrain
after Reprogramming
We further investigated whether the human astrocyte-converted
neurons can survive in the mouse brain in vivo. To distinguish the
human astrocyte-converted neurons from pre-existing mouse
neurons inside the brain, we used EGFP-lentiviruses to infect hu-
man astrocytes before small-molecule treatment so that human
astrocyte-converted neurons were mostly labeled by EGFP (Fig-
ure 7A). At 14 days after initial small-molecule treatment, we har-
vested the cells, which contained both converted neurons and
non-converted astrocytes, and injected them into the lateralc.
Figure 6. Evaluating the Essential Role of
Each Individual Small Molecule during
Astrocyte-Neuron Reprogramming
(A) Human astrocytes treated with 1% DMSO as a
control. NeuN, green; MAP2, red.
(B) A defined combination of nine small molecules
induced a massive number of neurons (14 days
post initial small-molecule treatment, the same for
the following removal experiments).
(C–F) Individual removal of DAPT (C), CHIR99021
(D), SB431542 (E), or LDN193189 (F) from the pool
of nine small molecules significantly reduced the
number of converted neurons.
(G) Removal of sonic hedgehog agonists SAG and
Purmo together slightly reduced the number of
converted neurons.
(H) Removal of VPA also slightly reduced the
neuronal number.
(I and J) Removal of Tzv (I) or TTNPB (J) did not
affect the neuronal conversion. Scale bars repre-
sent 20 mm.
(K) Quantitative analyses showing that DAPT is the
most potent reprogramming factor, followed by
CHIR99021, SB431542, and LDN193189. *p <
0.05; **p < 0.01; ***p < 0.001; one-way ANOVA
followed with Sidak’s multiple comparison test.
n = 3 batches.
Data are represented as mean ± SEM.ventricles in neonatal mice (Figure 7A). At 7 days post cell injec-
tion (DPI), we found a cluster of EGFP-labeled cells inside the
lateral ventricle, which were all immunopositive for human nuclei
(HuNu, Figure 7B), suggesting that these cells originated from
the injected human cells. Importantly, we found that many
EGFP-labeled human cells were immunopositive for neuronal
markers DCX (Figure 7B), MAP2, (Figure 7C), and NeuN (Fig-
ure 7D), suggesting that the human astrocyte-converted neurons
can survive in the mouse brain in vivo. Even 1 month after cell in-
jection, we were still able to identify clusters of EGFP-labeled
neurons in brain areas adjacent to the lateral ventricles such as
thalamus and striatum (Figure 7E), suggesting that the human
astrocyte-converted neurons might have migrated out of the
lateral ventricles and integrated into the local neural circuits. In
support of this notion, we found many synaptic puncta along
the dendrites of EGFP+ human neurons (Figure 7F), suggesting
that these grafted human neurons have established synaptic
connections with host neurons. Together, these in vivo experi-
ments demonstrate that our small-molecule-reprogrammed hu-
man neurons not only can survive in themouse brain but also can
integrate into the local neural circuits.
We have also attempted to reprogram mouse astrocytes into
neurons using our small-molecule strategy both in vitro and
in vivo. However, we did not succeed after many repeats, sug-
gesting that mouse and human astrocytes are significantly
different in response to the same set of small molecules (Han
et al., 2013). Nevertheless, we did find that the small-molecule-Cell Stem Cell 17, 735–747,treated mouse astrocytes in vivo ex-
pressed a much greater Nestin signal
than the vehicle control (Figures S7A
and S7B). Therefore, we isolated the
cortical tissue surrounding the small-molecule injection areas and cultured these in vitro. Interestingly,
the small-molecule-treated cortical tissue yielded many more
neurospheres than the vehicle control (Figures S7C–S7H). These
neurospheres could dissociate into neural stem cells and gave
rise to neurons, astrocytes, and oligodendrocytes (Figures S7I
and S7J). These data suggest that our small-molecule cocktail
was capable of stimulating cellular plasticity within the brain tis-
sue, but that it was not sufficient to enable in vivo reprogramming
of mouse astrocytes.
DISCUSSION
We demonstrate here that human astrocytes can be chemically
reprogrammed into functional neurons with a cocktail of nine
small molecules added in a sequential manner. Importantly,
these chemically reprogrammed human neurons are fully func-
tional, as demonstrated by long-term survival in cell cultures
and robust synaptic events and synchronous burst activities.
These chemically reprogrammed human neurons can also sur-
vive in the mouse brain in vivo and integrate into local circuits.
Mechanistically, the cocktail of small molecules may act
through epigenetic silencing of glial genes and transcriptional
activation of neural transcription factors such as NGN2 and
NEUROD1. The successful reprogramming of human astro-
cytes into functional neurons with chemically synthesized com-
pounds may potentially lead to a novel drug therapy for brain
repair.December 3, 2015 ª2015 Elsevier Inc. 743
Figure 7. In Vivo Survival and Integration of
Small-Molecule-Converted Human Neurons
in the Mouse Brain
(A) Schematic drawing showing the transplantation of
small-molecule-converted human neurons into the
mouse brains at postnatal day 1.
(B) GFP+ cells were identified around lateral ventricles
at 7 days post cell injection (7 DPI). Many GFP+ cells
were also positive for DCX (red), and all of the GFP+
cells were immunopositive for human nuclei (HuNu,
blue), indicating their human cell identity. n = 6 mice.
(C) At 11 DPI, some GFP+ cells were immunopositive
for MAP2 (red), indicating the survival and growth of
human neurons in the mouse brain in vivo. n = 6 mice.
(D) Some GFP+ human neurons, which were im-
munopositive for NeuN (red) and HuNu (cyan),
migrated into the adjacent striatum areas and
extended long neurites at 11 DPI.
(E) Human neurons, labeled by NeuN (red) and HuNu
(blue), survived for more than 1 month inside the
mouse brain and were surrounded bymouse neurons
(NeuN+ but HuNu). n = 2 mice.
(F) GFP+ human neurons were innervated by sur-
rounding neurons as indicated by many synaptic
puncta (SV2, red) along the GFP+ neurites (inset),
suggesting the synaptic integration of the trans-
planted human neurons into the local neural circuit.
n = 2mice. Scale bar of the fist image in (B) represents
50 mm. The rest of the scale bars represent 20 mm.Identification of Small Molecules Capable of
Reprogramming Astrocytes into Neurons
To identify the small molecules for astrocyte-neuron reprogram-
ming, we searched for small molecules that play crucial roles in
neurodevelopment and neurodifferentiation (Chambers et al.,
2009, 2012; Huangfu et al., 2008; Ladewig et al., 2012; Li et al.,
2011; Liu et al., 2013; Sirko et al., 2013; Zhang et al., 2011).
We tested a variety of small molecules (20 in total) targeting
signaling pathways critical for neurodevelopment, including
Noggin, BMP, TGFb, GSK3b, Wnt, RA, Notch, SHH, cAMP,744 Cell Stem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc.DNAmethylation, and histone deacetylation
or methylation. After testing hundreds of
different conditions, we identified a group
of nine small molecules (LDN193189,
SB431542, TTNPB, Tzv, CHIR99021,
DAPT, VPA, SAG, and Purmo) capable of re-
programming human astrocytes into neu-
rons. Importantly, adding these nine small
molecules together would cause severe
cell death, suggesting that some signaling
pathways cannot be inhibited simulta-
neously. A successful strategy is to add
fewer small molecules in a sequential
manner. By withdrawing each individual
molecule from the nine-molecule pool,
we found that DAPT plays the most signifi-
cant role in chemical reprogramming, fol-
lowed by CHIR99021, SB431542, and
LDN193189. Coincidentally, some of the
small molecules identified in our study
appear to be important in inducing neuraldifferentiation from human stem cells (hSCs) (Chambers et al.,
2009, 2012; Li et al., 2011), but the neuronal fate is quite different.
Our astrocyte-converted neurons are deep layer cortical neu-
rons or hippocampal neurons, possibly because our human as-
trocytes are cortical in origin and thus bear cortical lineage
traces. In contrast, Chambers et al. found that when hSCs
were treated with five small molecules (LDN193189 +
SB431542 + CHIR99021 + DAPT + SU5402), they differentiated
into spinal cord neurons (Chambers et al., 2012). A different
study reported that treating hSCs with three small molecules
(CHIR99021, SB431542, and compound E, a g-secretase inhib-
itor similar to DAPT used in our study) induced differentiation into
self-renewing neuroepithelial cells that can be further differenti-
ated into midbrain and hindbrain neurons (Li et al., 2011). These
studies, together with our own, suggest that different combina-
tions of small molecules, sometimes with a difference of only
one or two compounds, may result in different neuronal fates.
An alternative explanation for these different neuronal subtypes
is the different cell types to start with for reprogramming. This
is supported by our own observation that our small-molecule
protocol only works for human astrocytes with brain origin but
not for human spinal cord astrocytes or mouse astrocytes. It is
interesting to note that after we completed our studies, two
recent articles reported using small molecules to reprogram hu-
man or mouse fibroblasts into neurons (Hu et al., 2015; Li et al.,
2015). Comparing these two studies with our own, CHIR99021
emerged as an indispensable small molecule for chemical re-
programming of cells into neurons, and transcriptional activation
of NeuroD1 and Ngn2 was also observed after chemically re-
programming fibroblasts into neurons (Li et al., 2015). On the
other hand, in comparison to fibroblasts, we found that glial cells
can be more efficiently reprogrammed into neurons (67%) in a
short time (10 days) and survive for >5months in culture. Another
point worth mentioning is that our chemically reprogrammed
neurons are forebrain glutamatergic neurons, which share a
close lineage with the cortical astrocytes that they come from.
It can be challenging to reprogram fibroblasts into a specific sub-
type of neurons in a particular brain region.
Mechanisms of Small-Molecule-Mediated Astrocyte-
Neuron Reprogramming
The development of the central nervous system is under precise
temporal and spatial control by both intrinsic genetic programs
and external signals such as FGF, TGFb, SHH, BMP, Notch,
RA, and Wnt proteins (Hur and Zhou, 2010; Miller and Gauthier,
2007). We have tested various chemical compounds that may
activate or inhibit these signaling pathways during our search
for small molecules to convert astrocytes into neurons. One sur-
prising finding is that RA, which plays a critical role in neural stem
cell proliferation and differentiation, appears to be dispensable
for astrocyte-neuron conversion. Another unexpected finding is
that SHH, one of the major organizing signals in brain and spinal
cord development (Dessaud et al., 2008; Sirko et al., 2013), also
seems to be not absolutely required for astrocyte-neuron con-
version. Therefore, the mechanism of reprogramming astrocytes
into neurons clearly differs from that of neurodevelopment or
neurodifferentiation. One possible explanation is that neural
development or differentiation starts from neural stem/progeni-
tor cells, whereas our reprogramming process starts from astro-
cytes, which are the progeny of neural stem cells. RA and SHH
may be upstream of astroglial fate determination and therefore
not required for astrocyte-neuron reprogramming. On the other
hand, it is important to note that our current astrocyte-neuron re-
programming strategy mainly results in glutamatergic neurons. It
is possible that RA and SHHmay be important for the conversion
of astrocytes into other subtypes of neurons such as dopami-
nergic or GABAergic neurons.
Both epigenetic and transcriptional regulations appear to be
involved in our chemical reprogramming process. Our epigeneticCellanalyses revealed a significant increase of DNA methylation in
the promoter region of GFAP gene, particularly at the flanking
sites of two transcription factors’ (STAT3 and AP1) binding re-
gion, consistent with previous studies on epigenetic regulation
of astroglial fate (Cheng et al., 2011; Condorelli et al., 1994).
The epigenetic silencing of GFAP promoter through DNAmethyl-
ation may explain the downregulation of the GFAP transcrip-
tional level after small-molecule treatment. On the other hand,
regulation of NGN2 appears to bemediated by histonemodifica-
tion, as shown by an increase of H3K4 methylation in its pro-
moter region and a decrease of H3K27 methylation at the TSS.
Our results are consistent with a previous finding regarding the
regulation of NGN2 through histone modification (Hirabayashi
et al., 2009). The activation of NGN2 promoter is consistent
with our transcriptional analyses showing >200-fold increase of
the NGN2 transcriptional level after small-molecule treatment.
Therefore, our chemical reprogramming is mediated by epige-
netic silencing of glial genes and transcriptional activation of
neural transcriptional factors.
Conclusion
Our studies demonstrate the proof of principle that human astro-
cytes can be chemically reprogrammed into neurons. Impor-
tantly, our chemical reprogramming protocol is effective for
human astrocytes, but not mouse astrocytes. Among human as-
trocytes, our protocol is effective for brain astrocytes, but not
spinal cord astrocytes. Therefore, different glial cell lineages
may be sensitive to different sets of small molecules, suggesting
that different neurological disorders may require different chem-
icals to regenerate specific subtypes of neurons. Another chal-
lenge ahead is how to effectively deliver small molecules across
the blood-brain-barrier to the injured or diseased brain areas.
After delivery to the brain, how to chemically reprogram reactive
glial cells with less effect on normal glial cells also needs to be
resolved. Regardless of the challenges, chemical reprogram-
ming of human astrocytes into functional neurons provides a
novel approach to regenerate neurons for future brain repair.
EXPERIMENTAL PROCEDURES
Human Astrocyte Culture
Human astrocytes were purchased from ScienCell (HA1800) or GIBCO (N7805-
100). Human astrocytes were primary cultures obtained from human fetal brain
tissue. They were isolated and maintained in the presence of 10% FBS, which
will essentially cause any progenitor cells to differentiate. Human astrocytes
were subcultured when they were over 90% confluent. For subculture, cells
were trypsinized by TrypLE Select (Invitrogen), centrifuged for 5 min at
900 rpm, re-suspended, and plated in a culture medium consisting of DMEM/
F12 (GIBCO), 10% FBS (GIBCO), penicillin/streptomycin (GIBCO), and
3.5 mM glucose (Sigma), supplemented with B27 (GIBCO), 10 ng/ml epidermal
growth factor (EGF, Invitrogen), and 10 ng/ml fibroblast growth factor 2 (FGF2,
Invitrogen). Cells were maintained at 37C in humidified air with 5% CO2.
Reprogramming Human Astrocytes into Neurons
The astrocytes were cultured on poly-D-lysine (Sigma) coated coverslips
(12 mm) at a density of 50,000 cells per coverslip in 24-well plates (BD Biosci-
ences). The cells were cultured in human astrocyte medium until 90% conflu-
ence. At D0 before reprogramming, half of the culturemediumwas replaced by
N2 medium consisting of DMEM/F12 (GIBCO), penicillin/streptomycin
(GIBCO), and N2 supplements (GIBCO). The following day (D1), the culture
medium was completely replaced by N2 medium supplemented with small
molecules, or with 1% DMSO in control group. For most of the experimentsStem Cell 17, 735–747, December 3, 2015 ª2015 Elsevier Inc. 745
using nine molecules for reprogramming (MCM treatment), astrocytes were
treated with TTNPB (0.5 mM, Tocris #0761), SB431542 (5 mM, Tocris #1614),
LDN193189 (0.25 mM, Sigma #SML0559), and Tzv (0.5 mM, Cayman #14245)
for 2 days. At D3, the culture medium was replaced with a different set of small
molecules including CHIR99021 (1.5 mM, Tocris #4423), DAPT (5 mM, Sigma
#D5942), VPA (0.5 mM, Cayman #13033), and Tzv (0.5 mM). At D5, VPA
was withdrawn by replacing the medium with medium containing only
CHIR99021 (1.5 mM), DAPT (5 mM), and Tzv (0.5 mM). At D7, the medium
was replaced again with medium containing SAG (0.1 mM, Cayman #11914),
Purmo (0.1 mM, Cayman #10009634) and Tzv (0.5 mM). At D9, the medium
was completely replaced with neuronal differentiation medium (NDM), which
included DMEM/F12 (GIBCO), 0.5% FBS (GIBCO), 3.5 mM glucose (Sigma),
penicillin/streptomycin (GIBCO), and N2 supplement (GIBCO). 200 ml NDM
was added into each well every week to keep the osmolarity constant. To pro-
mote synaptic maturation of converted neurons, BDNF (20 ng/ml, Invitrogen),
IGF-1 (10 ng/ml, Invitrogen), and NT3 (10 ng/ml, Invitrogen) were added in
NDM at D9 and were refreshed every 4 days until D30 (Song et al., 2002).
To examine whether our human astrocytes contain any neural stem cells, we
cultured human astrocytes in NDM supplemented with BDNF (20 ng/ml), NT3
(10 ng/ml), and NGF (10 ng/ml) for 1 month. The growth factors were refreshed
every 3–4 days.
The humanNPCs derived from human pluripotent stem cells were a gift from
Dr. Fred Gage. The NPCswere cultured in poly-L-ornithine and laminin-coated
coverslips with neuronal proliferation medium including DMEM/F12, penicillin/
streptomycin, B27 supplement, N2 supplement, and FGF2 (20 ng/ml) (GIBCO).
Data and Statistical Analysis
Cell counting was performed by taking images at several randomly chosen
fields per coverslip and analyzed by Image J software. The fluorescence inten-
sity was analyzed by Image J software. Data were represented as mean ±
SEM. Student’s t test was used for the comparison between two groups of
data. One-way ANOVA and post hoc tests were used for statistical analyses
of data from multiple groups.
Additional methods can be found in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures, Supplemental
Experimental Procedures, and a Small-Molecule Screening Table and can be
found with this article online at http://dx.doi.org/10.1016/j.stem.2015.09.012.
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